<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942602</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0281</org_study_id>
    <nct_id>NCT02942602</nct_id>
  </id_info>
  <brief_title>Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1) to test HDL function comprehensively in healthy and diseased individuals; 2) to evaluate
      if this test correlates with cardiovascular risk, independent of traditional risk factors; 3)
      and to differentiate effects of lipid-modifying or antiatherosclerotic drugs on HDL function
      and composition
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cholesterol efflux capacity (%)</measure>
    <time_frame>Change of HDL functions from baseline to 8 weeks</time_frame>
    <description>[3H-cholesterol (µCi) in medium containing HDL/(3H-cholesterol {µCi} in medium containing HDL+µCi of 3H-cholesterol {µCi} in cells)] x 100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial NO production (Arbitrary unit)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>measured with nitrate assay kit and expressed as relative amount compared to control (no HDL treatment sample)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VCAM-1 expression (Arbitrary unit)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>western blotting of VCAM-1 protein and expressed as relative amount compared to control (no HDL treatment sample)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ROS generation (Arbitrary unit)</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>fluorescence intensity measurement using dichlorodihydrofluorescein diacetate and expressed as relative amount compared to control (no HDL treatment sample)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ApoA-I</measure>
    <time_frame>Change of HDL associated proteins from each patient at baseline and at 8 weeks</time_frame>
    <description>quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoA-II</measure>
    <time_frame>Change of HDL associated proteins from each patient at baseline and at 8 weeks</time_frame>
    <description>quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoC-I</measure>
    <time_frame>Change of HDL associated proteins from each patient at baseline and at 8 weeks</time_frame>
    <description>quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoC-II</measure>
    <time_frame>Change of HDL associated proteins from each patient at baseline and at 8 weeks</time_frame>
    <description>quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ApoC-III</measure>
    <time_frame>Change of HDL associated proteins from each patient at baseline and at 8 weeks</time_frame>
    <description>quantitation of intensity of western blot and expresses as relative amount to control (no HDL treatment sample)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lipid lowering treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholestyramine 8 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lipid lowering treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3 (EPA+DHA) 2 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lipid lowering treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 5 mg + Ezetimibe 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lipid lowering treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Life style modification for management of dyslipidemia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 mg</intervention_name>
    <description>The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.</description>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholestyramine 8 g</intervention_name>
    <description>The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.</description>
    <arm_group_label>Cholestyramine 8 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 2g</intervention_name>
    <description>The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.</description>
    <arm_group_label>Omega-3 (EPA+DHA) 2 g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg</intervention_name>
    <description>The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.</description>
    <arm_group_label>Atorvastatin 5 mg + Ezetimibe 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle modification</intervention_name>
    <description>The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.</description>
    <arm_group_label>Life style modification for management of dyslipidemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients who meet the 2013 American College of Cardiology/American Heart
             Association criteria for receiving lipid-lowering therapy

          -  Aged over 20

          -  Consent form signed

        Exclusion Criteria:

          -  pregnant or lactating women

          -  subjects with familial hypercholesterolemia

          -  uncontrolled hypertension or DM

          -  Thyroid dysfunction

          -  Active liver disease (transaminase or bilirubin &gt; 1.5 x NL)

          -  Serum creatinine &gt; 2 mg/dL

          -  Included in other clinical trials within 3 months

          -  using of other medication: fish oil, fibric acid derivatives, niacin, systemic
             corticosteroid, thiazolidinedione
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sang-Hak Lee, MD</last_name>
    <phone>82-2-2228-8456</phone>
    <email>SHL1106@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine,</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang-Hak Lee, MD</last_name>
      <phone>82-2-2228-8456</phone>
      <email>SHL1106@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Cholestyramine Resin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

